Cargando…

(89)Zr-PET imaging to predict tumor uptake of (177)Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma

[(177)Lu]Lu-DOTA-NNV003, a radioimmunoconjugate targeting CD37, is developed as novel radioimmunotherapy (RIT) treatment for patients with B cell non-Hodgkin’s lymphoma (NHL). Since patients are at risk for developing hematological toxicities due to CD37 expression on normal B cells, we aimed to dev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giesen, Danique, Hooge, Marjolijn N. Lub-de, Nijland, Marcel, Heyerdahl, Helen, Dahle, Jostein, de Vries, Elisabeth G. E., Pool, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012778/ https://www.ncbi.nlm.nih.gov/pubmed/35428777 http://dx.doi.org/10.1038/s41598-022-10139-6

Ejemplares similares

Anti-CD37 radioimmunotherapy with (177)Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro
por: Malenge, Marion M., et al.
Publicado: (2022)

Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate (177)Lu-NNV003
por: Maaland, Astri Fjelde, et al.
Publicado: (2019)

(89)Zr-Onartuzumab PET imaging of c-MET receptor dynamics
por: Pool, Martin, et al.
Publicado: (2017)

Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate (212)Pb-NNV003
por: Maaland, Astri Fjelde, et al.
Publicado: (2020)

(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
por: van der Veen, Elly L, et al.
Publicado: (2020)

CD38‐Targeted Theranostics of Lymphoma with (89)Zr/(177)Lu‐Labeled Daratumumab
por: Kang, Lei, et al.
Publicado: (2021)

(89)Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment
por: Pool, Martin, et al.
Publicado: (2017)

Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer (89)Zr-imgatuzumab
por: Pool, Martin, et al.
Publicado: (2016)

Evaluation of Candidate Theranostics for (227)Th/(89)Zr Paired Radioimmunotherapy of Lymphoma
por: Abou, Diane S., et al.
Publicado: (2023)

Experimental α-particle radioimmunotherapy of breast cancer using (227)Th-labeled p-benzyl-DOTA-trastuzumab
por: Abbas, Nasir, et al.
Publicado: (2011)

Biodistribution and Dosimetry of (177)Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
por: Repetto-Llamazares, Ada H V, et al.
Publicado: (2013)

In vitro characterisation of [(177)Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer
por: Hull, Ashleigh, et al.
Publicado: (2023)

(177)Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice
por: Repetto-Llamazares, Ada H. V., et al.
Publicado: (2014)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

(177)Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma
por: Malenge, Marion M., et al.
Publicado: (2020)

Anti-CD45 Radioimmunotherapy with (90)Y but Not (177)Lu Is Effective Treatment in a Syngeneic Murine Leukemia Model
por: Orozco, Johnnie J., et al.
Publicado: (2014)

Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models
por: Frost, Sofia H. L., et al.
Publicado: (2015)

First clinical experience with fractionated intracavitary radioimmunotherapy using [(177)Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study
por: Roll, Wolfgang, et al.
Publicado: (2023)

Role of CD8-positive cells in radioimmunotherapy utilizing (177)Lu-mAbs in an immunocompetent rat colon carcinoma model
por: Elgström, Erika, et al.
Publicado: (2015)

PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a (177)Lu-labeled αPD-L1 antibody
por: Ren, Jingyun, et al.
Publicado: (2021)

PET/CT Imaging of (89)Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys
por: Li, Wenping, et al.
Publicado: (2020)

The therapeutic effectiveness of (177)Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest
por: Pichard, Alexandre, et al.
Publicado: (2019)

Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with (89)Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts
por: ter Weele, Eva J., et al.
Publicado: (2015)

Comparative biodistribution analysis across four different (89)Zr-monoclonal antibody tracers—The first step towards an imaging warehouse
por: Bensch, Frederike, et al.
Publicado: (2018)

FDG PET/CT and Dosimetric Studies of (177)Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?
por: Løndalen, Ayca, et al.
Publicado: (2022)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
por: Waaijer, Stijn JH, et al.
Publicado: (2020)

Evaluation of the (177m)Lu-concentration in in-house produced (177)Lu-radiopharmaceuticals and commercially available Lutathera(®)
por: Balzer, Matthias, et al.
Publicado: (2023)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
por: Arveschoug, Anne Kirstine, et al.
Publicado: (2020)

Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

Pre-dosing with lilotomab prior to therapy with (177)Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
por: Stokke, Caroline, et al.
Publicado: (2018)

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of (177)Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
por: Løndalen, Ayca, et al.
Publicado: (2020)

Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats
por: Yousefnia, Hassan, et al.
Publicado: (2015)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Development of (89)Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration
por: Kol, Arjan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_01lc6hujmuvnhro98i8q8kvu0a